Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline Review, H2 2017

Global Markets Direct’s, ‘Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline Review, H2 2017’, provides an overview of the Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Coronary Artery Disease (CAD) (Ischemic Heart Disease) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Coronary Artery Disease (CAD) (Ischemic Heart Disease)

The report reviews pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Coronary Artery Disease (CAD) (Ischemic Heart Disease) therapeutics and enlists all their major and minor projects

The report assesses Coronary Artery Disease (CAD) (Ischemic Heart Disease) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Coronary Artery Disease (CAD) (Ischemic Heart Disease)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Coronary Artery Disease (CAD) (Ischemic Heart Disease)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Coronary Artery Disease (CAD) (Ischemic Heart Disease) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Amarantus Bioscience Holdings Inc

AnGes MG Inc

Angionetics Inc

Ascendia Pharmaceuticals LLC

AstraZeneca Plc

Athera Biotechnologies AB

Bayer AG

Biscayne Pharmaceuticals Inc

Capricor Therapeutics Inc

CardioVascular BioTherapeutics Inc

CSL Ltd

Gilead Sciences Inc

Human Stem Cells Institute

Idorsia Ltd

Juventas Therapeutics Inc

Lee's Pharmaceutical Holdings Ltd

LipimetiX Development Inc

Livzon Pharmaceutical Group Inc

Lonestar Heart Inc

MedImmune LLC

Merck & Co Inc

Nuo Therapeutics Inc

Pfizer Inc

Proteon Therapeutics Inc

Resverlogix Corp

Tasly Pharmaceutical Group Co Ltd

The Medicines Company

Verseon Corp

VESSL Therapeutics Ltd

ViroMed Co Ltd

XyloCor Therapeutics Inc

Table of Contents

Table of Contents

Table of Contents 2

List of Tables 5

List of Figures 6

Introduction 7

Global Markets Direct Report Coverage 7

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Overview 8

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Development 9

Pipeline Overview 9

Pipeline by Companies 10

Pipeline by Universities/Institutes 14

Products under Development by Companies 15

Products under Development by Universities/Institutes 18

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Therapeutics Assessment 19

Assessment by Target 19

Assessment by Mechanism of Action 22

Assessment by Route of Administration 24

Assessment by Molecule Type 26

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Companies Involved in Therapeutics Development 28

Amarantus Bioscience Holdings Inc 28

AnGes MG Inc 28

Angionetics Inc 29

Ascendia Pharmaceuticals LLC 29

AstraZeneca Plc 30

Athera Biotechnologies AB 30

Bayer AG 31

Biscayne Pharmaceuticals Inc 31

Capricor Therapeutics Inc 32

CardioVascular BioTherapeutics Inc 32

CSL Ltd 33

Gilead Sciences Inc 33

Human Stem Cells Institute 34

Idorsia Ltd 34

Juventas Therapeutics Inc 35

Lee's Pharmaceutical Holdings Ltd 35

LipimetiX Development Inc 36

Livzon Pharmaceutical Group Inc 36

Lonestar Heart Inc 37

MedImmune LLC 37

Merck & Co Inc 38

Nuo Therapeutics Inc 39

Pfizer Inc 39

Proteon Therapeutics Inc 40

Resverlogix Corp 40

Tasly Pharmaceutical Group Co Ltd 40

The Medicines Company 41

Verseon Corp 42

VESSL Therapeutics Ltd 42

ViroMed Co Ltd 43

XyloCor Therapeutics Inc 43

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Drug Profiles 44

ACT-246475 - Drug Profile 44

AEM-28 - Drug Profile 45

AEM-2802 - Drug Profile 47

ALD-201 - Drug Profile 48

alferminogene tadenovec - Drug Profile 50

alprostadil - Drug Profile 55

AMRS-001 - Drug Profile 57

anacetrapib - Drug Profile 66

apabetalone - Drug Profile 69

APT-402 - Drug Profile 82

AZD-5069 - Drug Profile 83

AZD-5718 - Drug Profile 85

BAT-2094 - Drug Profile 86

beperminogene perplasmid - Drug Profile 87

BIS-5409 - Drug Profile 92

bivalirudin trifluoroacetate - Drug Profile 93

cangrelor tetrasodium - Drug Profile 94

CAP-1002 - Drug Profile 98

CAP-2003 - Drug Profile 105

clopidogrel bisulphate - Drug Profile 107

COR-2 - Drug Profile 108

Cryocell - Drug Profile 109

CSL-112 - Drug Profile 110

CVBT-141H - Drug Profile 112

dalcetrapib - Drug Profile 113

Gemacell - Drug Profile 117

JVS-100 - Drug Profile 118

MEDI-6012 - Drug Profile 123

MultiGeneAngio - Drug Profile 125

MZ-004 - Drug Profile 126

Neovasculgen - Drug Profile 128

PC-mAb - Drug Profile 129

PF-06282999 - Drug Profile 132

PMC-6 - Drug Profile 133

PR-15 - Drug Profile 134

Proteins for Ischemic Heart Disease - Drug Profile 136

ranolazine ER - Drug Profile 137

Recombinant Protein for Cardiovascular Diseases - Drug Profile 140

Rejuveinix - Drug Profile 141

rivaroxaban - Drug Profile 142

Small Molecules for Ischemic Heart Disease - Drug Profile 159

Small Molecules to Inhibit Gamma Butyrobetaine for Coronary Heart Disease - Drug Profile 160

Small Molecules to Inhibit Thrombin for Cardiovascular Diseases - Drug Profile 161

TSL-0202 - Drug Profile 163

vericiguat - Drug Profile 164

VM-202 - Drug Profile 166

vonapanitase - Drug Profile 170

XC-001 - Drug Profile 176

Xcel-hCardP - Drug Profile 177

Xcel-hCM - Drug Profile 178

ZK-001 - Drug Profile 179

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Dormant Projects 181

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Discontinued Products 185

Coronary Artery Disease (CAD) (Ischemic Heart Disease) - Product Development Milestones 187

Featured News & Press Releases 187

Appendix 197

Methodology 197

Coverage 197

Secondary Research 197

Primary Research 197

Expert Panel Validation 197

Contact Us 197

Disclaimer 198

List of Tables

List of Tables

Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Number of Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Number of Products under Development by Universities/Institutes, H2 2017

Products under Development by Companies, H2 2017

Products under Development by Companies, H2 2017 (Contd..1), H2 2017

Products under Development by Companies, H2 2017 (Contd..2), H2 2017

Products under Development by Universities/Institutes, H2 2017

Number of Products by Stage and Target, H2 2017

Number of Products by Stage and Target, H2 2017 (Contd..1), H2 2017

Number of Products by Stage and Mechanism of Action, H2 2017

Number of Products by Stage and Route of Administration, H2 2017

Number of Products by Stage and Molecule Type, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Amarantus Bioscience Holdings Inc, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by AnGes MG Inc, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Angionetics Inc, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Ascendia Pharmaceuticals LLC, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by AstraZeneca Plc, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Athera Biotechnologies AB, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Bayer AG, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Biscayne Pharmaceuticals Inc, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Capricor Therapeutics Inc, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by CardioVascular BioTherapeutics Inc, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by CSL Ltd, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Gilead Sciences Inc, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Human Stem Cells Institute, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Idorsia Ltd, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Juventas Therapeutics Inc, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Lee's Pharmaceutical Holdings Ltd, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by LipimetiX Development Inc, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Livzon Pharmaceutical Group Inc, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Lonestar Heart Inc, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by MedImmune LLC, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Merck & Co Inc, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Nuo Therapeutics Inc, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Pfizer Inc, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Proteon Therapeutics Inc, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Resverlogix Corp, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Tasly Pharmaceutical Group Co Ltd, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by The Medicines Company, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by Verseon Corp, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by VESSL Therapeutics Ltd, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by ViroMed Co Ltd, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Pipeline by XyloCor Therapeutics Inc, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Dormant Projects, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Dormant Projects, H2 2017 (Contd..1), H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Dormant Projects, H2 2017 (Contd..2), H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Dormant Projects, H2 2017 (Contd..3), H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Discontinued Products, H2 2017

Coronary Artery Disease (CAD) (Ischemic Heart Disease) – Discontinued Products, H2 2017 (Contd..1), H2 2017

List of Figures

List of Figures

Number of Products under Development for Coronary Artery Disease (CAD) (Ischemic Heart Disease), H2 2017

Number of Products under Development by Companies, H2 2017

Number of Products by Top 10 Targets, H2 2017

Number of Products by Stage and Top 10 Targets, H2 2017

Number of Products by Top 10 Mechanism of Actions, H2 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017

Number of Products by Routes of Administration, H2 2017

Number of Products by Stage and Routes of Administration, H2 2017

Number of Products by Molecule Types, H2 2017

Number of Products by Stage and Molecule Types, H2 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports